Kevin Jennings alters Coquette menu as GLP-1 drug use surges
Updated
Updated · WRAL News · May 4
Kevin Jennings alters Coquette menu as GLP-1 drug use surges
5 articles · Updated · WRAL News · May 4
At Raleigh's Coquette, Jennings is adding smaller, protein-focused dishes at lower prices as KFF estimates one in eight US adults now take GLP-1 drugs.
Jennings, who also uses GLP-1s, said the restaurant industry must adapt as more diners want lighter portions and fewer sides, while national chains have made similar menu changes.
Duke's Dr Will Yancy said about 75% of new patients ask for GLP-1s, but warned results vary and lifestyle changes still matter despite the drugs' growing popularity.
As GLP-1 drugs reshape our appetites, will they also diminish the joy and culture of eating together?
With millions spending less on food and impulse buys, which industries will unexpectedly shrink or boom in this new economy?
What happens to the body and mind when the medication stops and the full force of cravings and hunger returns?
The $150 Billion Impact: GLP-1 Drugs Slash Appetite and Force Restaurants to Rethink Portions by 2030
Overview
The rapid rise of GLP-1 medications since 2025 has transformed the restaurant industry by reducing users' appetites and altering their food preferences. This shift caused a notable decline in fast-food dinner and alcohol sales, prompting restaurants to rethink menus with smaller, protein-focused portions and flexible customization. Both chains and independents are innovating to meet these new demands, balancing reduced food waste and operational challenges. The upcoming availability of oral GLP-1 drugs and expected price drops will accelerate user growth, driving further cultural changes and fueling new nutrition-focused products. This evolving landscape pushes the industry toward a science-informed, customer-centric model emphasizing satisfaction per bite and holistic nutrition services.